{"id":"W4399122010","doi":"10.1200/jco.2024.42.16_suppl.1005","title":"Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Breast cancer; Oncology; Triple-negative breast cancer; Internal medicine; Triple negative; Cancer; Gynecology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008678516,0.0005330647,0.0006843403,0.000209706,0.0002813685,0.0005690622,0.0002984474,0.0004936344,0.003330337],"category_scores_gemma":[0.0004457565,0.0002240382,0.0004232402,0.0002179811,0.0003017632,0.0004684158,0.0003454578,0.001227826,0.0005269088],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007586448,"about_ca_system_score_gemma":0.00114012,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00100683,"about_ca_topic_score_gemma":0.003999332,"domain_scores_codex":[0.9997942,0.00007361571,0.00001241916,0.00003925995,0.0000238167,0.00005670269],"domain_scores_gemma":[0.9996873,0.00003642348,0.00004283672,0.00002491994,0.00002424682,0.0001844312],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6473396,0.06131323,0.0447621,0.0009247497,0.001137855,0.0004553432,0.0004932589,0.00207674,0.07028598,0.0006457847,0.008622177,0.1619432],"study_design_scores_gemma":[0.2292559,0.6178894,0.1057037,0.0001446051,0.001169423,0.001741923,0.0003784897,0.003204545,0.0145825,0.0009042908,0.02497567,0.00004954748],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963671,0.001096889,0.0001228267,0.0001282709,0.00003692124,0.0005282859,0.0006544818,0.00001944034,0.001045847],"genre_scores_gemma":[0.9926522,0.0007547659,0.0006504848,0.0003318368,0.00004214649,0.000779305,0.002672092,0.00001144836,0.002105727],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003330337,"threshold_uncertainty_score":0.01114112,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1377817727281921,"score_gpt":0.5451264201042444,"score_spread":0.4073446473760523,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}